281 related articles for article (PubMed ID: 34479036)
21. Conjugation of 4-aminosalicylate with thiazolinones afforded non-cytotoxic potent in vitro and in vivo anti-inflammatory hybrids.
Abdu-Allah HHM; Abdelmoez AAB; Tarazi H; El-Shorbagi AA; El-Awady R
Bioorg Chem; 2020 Jan; 94():103378. PubMed ID: 31677858
[TBL] [Abstract][Full Text] [Related]
22. Celastrol modulates inflammation through inhibition of the catalytic activity of mediators of arachidonic acid pathway: Secretory phospholipase A
Joshi V; Venkatesha SH; Ramakrishnan C; Nanjaraj Urs AN; Hiremath V; Moudgil KD; Velmurugan D; Vishwanath BS
Pharmacol Res; 2016 Nov; 113(Pt A):265-275. PubMed ID: 27597642
[TBL] [Abstract][Full Text] [Related]
23. Novel 1,2,4-triazine-quinoline hybrids: The privileged scaffolds as potent multi-target inhibitors of LPS-induced inflammatory response via dual COX-2 and 15-LOX inhibition.
Ghanim AM; Rezq S; Ibrahim TS; Romero DG; Kothayer H
Eur J Med Chem; 2021 Jul; 219():113457. PubMed ID: 33892270
[TBL] [Abstract][Full Text] [Related]
24. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?
Fiorucci S; Meli R; Bucci M; Cirino G
Biochem Pharmacol; 2001 Dec; 62(11):1433-8. PubMed ID: 11728379
[TBL] [Abstract][Full Text] [Related]
25. Thiazoles and Thiazolidinones as COX/LOX Inhibitors.
Liaras K; Fesatidou M; Geronikaki A
Molecules; 2018 Mar; 23(3):. PubMed ID: 29562646
[TBL] [Abstract][Full Text] [Related]
26. Novel class of benzimidazole-thiazole hybrids: The privileged scaffolds of potent anti-inflammatory activity with dual inhibition of cyclooxygenase and 15-lipoxygenase enzymes.
Maghraby MT; Abou-Ghadir OMF; Abdel-Moty SG; Ali AY; Salem OIA
Bioorg Med Chem; 2020 Apr; 28(7):115403. PubMed ID: 32127262
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and biological evaluation of novel pyrazole sulfonamide derivatives as dual COX-2/5-LOX inhibitors.
Gedawy EM; Kassab AE; El Kerdawy AM
Eur J Med Chem; 2020 Mar; 189():112066. PubMed ID: 31982653
[TBL] [Abstract][Full Text] [Related]
28. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy.
Celotti F; Durand T
Prostaglandins Other Lipid Mediat; 2003 Jul; 71(3-4):147-62. PubMed ID: 14518558
[TBL] [Abstract][Full Text] [Related]
29. Rationalization of physicochemical characters of 1,5-diarylpyrazole analogs as dual (COX-2/LOX-5) inhibitors: a QSAR approach.
Revathi S; Gupta AK; Soni LK; Kavitha S; Wagh R; Kaskhedikar SG
J Pharm Biomed Anal; 2006 Sep; 42(2):283-9. PubMed ID: 16781106
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and evaluation of novel diaryl-1,5-diazoles derivatives bearing morpholine as potent dual COX-2/5-LOX inhibitors and antitumor agents.
Li Z; Wang ZC; Li X; Abbas M; Wu SY; Ren SZ; Liu QX; Liu Y; Chen PW; Duan YT; Lv PC; Zhu HL
Eur J Med Chem; 2019 May; 169():168-184. PubMed ID: 30877972
[TBL] [Abstract][Full Text] [Related]
31. New approaches to the modulation of the cyclooxygenase-2 and 5-lipoxygenase pathways.
González-Périz A; Clària J
Curr Top Med Chem; 2007; 7(3):297-309. PubMed ID: 17305572
[TBL] [Abstract][Full Text] [Related]
32. Dual COX-2 and 15-LOX inhibition study of novel 4-arylidine-2-mercapto-1-phenyl-1H-imidazolidin-5(4H)-ones: Design, synthesis, docking, and anti-inflammatory activity.
Osman NA; Soltan MK; Rezq S; Flaherty J; Romero DG; Abdelkhalek AS
Arch Pharm (Weinheim); 2024 May; 357(5):e2300615. PubMed ID: 38315093
[TBL] [Abstract][Full Text] [Related]
33. Synthesis of novel hybrids of pyrazole and coumarin as dual inhibitors of COX-2 and 5-LOX.
Shen FQ; Wang ZC; Wu SY; Ren SZ; Man RJ; Wang BZ; Zhu HL
Bioorg Med Chem Lett; 2017 Aug; 27(16):3653-3660. PubMed ID: 28720504
[TBL] [Abstract][Full Text] [Related]
34. New hybrid molecules combining benzothiophene or benzofuran with rhodanine as dual COX-1/2 and 5-LOX inhibitors: Synthesis, biological evaluation and docking study.
El-Miligy MMM; Hazzaa AA; El-Messmary H; Nassra RA; El-Hawash SAM
Bioorg Chem; 2017 Jun; 72():102-115. PubMed ID: 28390993
[TBL] [Abstract][Full Text] [Related]
35. Novel N-substituted indole Schiff bases as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase enzymes: Synthesis, biological activities in vitro and docking study.
Lamie PF; Ali WAM; Bazgier V; Rárová L
Eur J Med Chem; 2016 Nov; 123():803-813. PubMed ID: 27541263
[TBL] [Abstract][Full Text] [Related]
36. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs.
Charlier C; Michaux C
Eur J Med Chem; 2003; 38(7-8):645-59. PubMed ID: 12932896
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases.
Rao PN; Chen QH; Knaus EE
J Med Chem; 2006 Mar; 49(5):1668-83. PubMed ID: 16509583
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of 3-[4-(amino/methylsulfonyl)phenyl]methylene-indolin-2-one derivatives as novel COX-1/2 and 5-LOX inhibitors.
Lai Y; Ma L; Huang W; Yu X; Zhang Y; Ji H; Tian J
Bioorg Med Chem Lett; 2010 Dec; 20(24):7349-53. PubMed ID: 21055929
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological evaluation of isoxazolo[4,5-d]pyridazin-4-(5H)-one analogues as potent anti-inflammatory agents.
Özadalı K; Özkanlı F; Jain S; Rao PP; Velázquez-Martínez CA
Bioorg Med Chem; 2012 May; 20(9):2912-22. PubMed ID: 22475926
[TBL] [Abstract][Full Text] [Related]
40. DuCLOX-2/5 inhibition: a promising target for cancer chemoprevention.
Gautam S; Roy S; Ansari MN; Saeedan AS; Saraf SA; Kaithwas G
Breast Cancer; 2017 Mar; 24(2):180-190. PubMed ID: 27558792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
